Скачать с ютуб FDA-Approved Treatment that Prevents Recurrent C. difficile Infection в хорошем качестве

FDA-Approved Treatment that Prevents Recurrent C. difficile Infection

Dr. Elizabeth Garner, MD, Chief Scientific Officer for Ferring Pharmaceuticals discusses C. difficile infection as a major health threat, its current standard of care, the reason for the recurrence of this contagious, serious, and sometimes life-threatening disease, and a novel FDA-approved treatment that prevents recurrent C. difficile infection in a unique way involving the gut microbiome. #CDifficileInfection Elizabeth Garner, MD, MPH is the US Chief Scientific Officer of Ferring Pharmaceuticals. Dr. Garner has nearly 30 years of experience in medicine and industry, and has expertise in clinical trial design and operations, regulatory strategy, medical affairs, safety and pharmacovigilance, as well as product due diligence assessment. Prior to joining Ferring in 2022, she held chief medical officer roles for ObsEva, a biotechnology company focused on women’s health, and Agile Therapeutics, a women’s healthcare company. Earlier, she held leadership roles in medical affairs at Myriad Genetics Laboratories and clinical development at Abbott Laboratories and Merck Research Laboratories. Elizabeth holds a medical degree from Harvard Medical School and has practiced in obstetrics and gynecology, gynecologic oncology, and internal medicine at Brigham and Women’s Hospital, Massachusetts General Hospital, and the Dana Farber Cancer Institute. In addition, she holds a master’s degree in public health from Harvard’s T.H. Chan School of Public Health.